{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:54:14Z","timestamp":1774965254422,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"DOI":"10.1038\/s41418-026-01729-2","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:32:40Z","timestamp":1774956760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GBA1 F213I mutation increases the expression of LCN2 promoting neurodegeneration"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2208-9628","authenticated-orcid":false,"given":"Shuxia","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-0967","authenticated-orcid":false,"given":"Duan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-7897","authenticated-orcid":false,"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"key":"1729_CR2","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.59717\/j.xinn-med.2024.100073","volume":"2","author":"J Gao","year":"2024","unstructured":"Gao J, Gao Y, Wang H, Han C, Meng F. Late-stage Parkinson\u2019s disease: Skilled walking with a neuroprosthesis. The Innovation Med. 2024;2:100073.","journal-title":"The Innovation Med"},{"key":"1729_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bcmd.2006.11.003","volume":"38","author":"FY Choy","year":"2007","unstructured":"Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, et al. Gaucher disease among Chinese patients: review on genotype\/phenotype correlation from 29 patients and identification of novel and rare alleles. Blood Cells Mol Dis. 2007;38:287\u201393.","journal-title":"Blood Cells Mol Dis"},{"key":"1729_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cytogfr.2018.04.003","volume":"41","author":"Y Chen","year":"2018","unstructured":"Chen Y, Sud N, Hettinghouse A, Liu CJ. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine Growth Factor Rev. 2018;41:65\u201374.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1729_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","volume":"139","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139:77\u201390.","journal-title":"J Neurochem"},{"key":"1729_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wu H, Tang B, Guo J. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease. Transl Neurodegener. 2024;13:48.","journal-title":"Transl Neurodegener"},{"key":"1729_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361:1651\u201361.","journal-title":"N Engl J Med"},{"key":"1729_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","volume":"20","author":"S Lesage","year":"2011","unstructured":"Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, et al. Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease. Hum Mol Genet. 2011;20:202\u201310.","journal-title":"Hum Mol Genet"},{"key":"1729_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84:880\u20137.","journal-title":"Neurology"},{"key":"1729_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114402","volume":"187","author":"M Horowitz","year":"2022","unstructured":"Horowitz M, Braunstein H, Zimran A, Revel-Vilk S, Goker-Alpan O. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Adv Drug Deliv Rev. 2022;187:114402.","journal-title":"Adv Drug Deliv Rev"},{"key":"1729_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann J, Bras J, Deas E, O\u2019Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain. 2009;132:1783\u201394.","journal-title":"Brain"},{"key":"1729_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/jhg.2014.110","volume":"60","author":"Z Yu","year":"2015","unstructured":"Yu Z, Wang T, Xu J, Wang W, Wang G, Chen C, et al. Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson\u2019s disease. J Hum Genet. 2015;60:85\u201390.","journal-title":"J Hum Genet"},{"key":"1729_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","volume":"11","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shu L, Sun Q, Zhou X, Pan H, Guo J, et al. Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson\u2019s Disease: A Meta-Analysis. Front Mol Neurosci. 2018;11:43.","journal-title":"Front Mol Neurosci"},{"key":"1729_CR14","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/mds.28191","volume":"35","author":"Y Chen","year":"2020","unstructured":"Chen Y, Gu X, Ou R, Zhang L, Hou Y, Liu K, et al. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson\u2019s Disease. Mov Disord. 2020;35:2046\u201355.","journal-title":"Mov Disord"},{"key":"1729_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14:36.","journal-title":"Mol Neurodegener"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1093\/brain\/awu291","volume":"137","author":"I Fishbein","year":"2014","unstructured":"Fishbein I, Kuo YM, Giasson BI, Nussbaum RL. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain. 2014;137:3235\u201347.","journal-title":"Brain"},{"key":"1729_CR17","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/brain\/awx221","volume":"140","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards A, Wegrzynowicz M, Rusconi R, Deangeli G, Di Monte DA, Spillantini MG, et al. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain. 2017;140:2706\u201321.","journal-title":"Brain"},{"key":"1729_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","volume":"13","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kim D, Kim S, Kim S, Karuppagounder SS, Kwon SH, et al. \u03b1-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener. 2018;13:1.","journal-title":"Mol Neurodegener"},{"key":"1729_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41531-023-00571-4","volume":"9","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang Y, Wan J, Zhao Y, Pan H, Zeng Q, et al. Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9:129.","journal-title":"NPJ Parkinsons Dis"},{"key":"1729_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.892457","volume":"13","author":"JN Guo","year":"2022","unstructured":"Guo JN, Guan M, Jiang N, Li N, Li YJ, Zhang J, et al. Establishment and Phenotypic Analysis of the Novel Gaucher Disease Mouse Model With the Partially Humanized Gba1 Gene and F213I Mutation. Front Genet. 2022;13:892457.","journal-title":"Front Genet"},{"key":"1729_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106899","volume":"209","author":"S Wen","year":"2025","unstructured":"Wen S, Li Y, Xiang W, Shen F, Jiang N, Ma D, et al. A novel mouse model of chronic neuronopathic Gaucher disease exhibits Parkinson\u2019s disease-like phenotypes. Neurobiol Dis. 2025;209:106899.","journal-title":"Neurobiol Dis"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jleuko\/qiad157","volume":"116","author":"R Afridi","year":"2024","unstructured":"Afridi R, Kim JH, Bhusal A, Lee WH, Suk K. Lipocalin-2 as a mediator of neuroimmune communication. J Leukoc Biol. 2024;116:357\u201368.","journal-title":"J Leukoc Biol"},{"key":"1729_CR23","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1096\/fj.11-202457","volume":"26","author":"PJ Naude","year":"2012","unstructured":"Naude PJ, Nyakas C, Eiden LE, Ait-Ali D, van der Heide R, Engelborghs S, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer\u2019s disease. FASEB J. 2012;26:2811\u201323.","journal-title":"FASEB J"},{"key":"1729_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.839118","volume":"16","author":"JH Kim","year":"2022","unstructured":"Kim JH, Kwon O, Bhusal A, Lee J, Hwang EM, Ryu H, et al. Neuroinflammation Induced by Transgenic Expression of Lipocalin-2 in Astrocytes. Front Cell Neurosci. 2022;16:839118.","journal-title":"Front Cell Neurosci"},{"key":"1729_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s13311-022-01333-5","volume":"20","author":"JH Kim","year":"2023","unstructured":"Kim JH, Kang RJ, Hyeon SJ, Ryu H, Joo H, Bu Y, et al. Lipocalin-2 Is a Key Regulator of Neuroinflammation in Secondary Traumatic and Ischemic Brain Injury. Neurotherapeutics. 2023;20:803\u201321.","journal-title":"Neurotherapeutics"},{"key":"1729_CR26","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1523\/JNEUROSCI.4261-15.2016","volume":"36","author":"BW Kim","year":"2016","unstructured":"Kim BW, Jeong KH, Kim JH, Jin M, Kim JH, Lee MG, et al. Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System. J Neurosci. 2016;36:5608\u201322.","journal-title":"J Neurosci"},{"key":"1729_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.798335","volume":"13","author":"L Wei","year":"2021","unstructured":"Wei L, Du Y, Xie Y, Yu X, Chen H, Qiu Y. Lipocalin-2 Regulates Hippocampal Microglial Activation in Poststroke Depression. Front Aging Neurosci. 2021;13:798335.","journal-title":"Front Aging Neurosci"},{"key":"1729_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.25303","volume":"102","author":"Y Fan","year":"2024","unstructured":"Fan Y, Li X, Ma J, Yang D, Liang K, Shen Y, et al. Increased plasma lipocalin-2 levels are associated with nonmotor symptoms and neuroimaging features in patients with Parkinson\u2019s disease. J Neurosci Res. 2024;102:e25303.","journal-title":"J Neurosci Res"},{"key":"1729_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948615","volume":"13","author":"N Xing","year":"2022","unstructured":"Xing N, Dong Z, Wu Q, Kan P, Han Y, Cheng X, et al. Identification and validation of key molecules associated with humoral immune modulation in Parkinson\u2019s disease based on bioinformatics. Front Immunol. 2022;13:948615.","journal-title":"Front Immunol"},{"key":"1729_CR30","doi-asserted-by":"publisher","unstructured":"Homann J, Smith AG, Morgan S, Frick EA, Liu F, Viallon V, et al. Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson\u2019s disease and overlap with other neurodegenerative disorders. medRxiv [Preprint]. 2025. https:\/\/doi.org\/10.1101\/2025.07.30.25332433.","DOI":"10.1101\/2025.07.30.25332433"},{"key":"1729_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01934-x","volume":"17","author":"A Vardi","year":"2020","unstructured":"Vardi A, Ben-Dor S, Cho SM, Kalinke U, Spanier J, Futerman AH. Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease. J Neuroinflammation. 2020;17:265.","journal-title":"J Neuroinflammation"},{"key":"1729_CR32","doi-asserted-by":"crossref","unstructured":"Kim SL, Shin MW, Kim SW. Lipocalin 2 activates the NLRP3 inflammasome via LPS\u2011induced NF\u2011kappaB signaling and plays a role as a pro\u2011inflammatory regulator in murine macrophages. Mol Med Rep. 2022;26:358.","DOI":"10.3892\/mmr.2022.12875"},{"key":"1729_CR33","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/302925","volume":"66","author":"V Koprivica","year":"2000","unstructured":"Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000;66:1777\u201386.","journal-title":"Am J Hum Genet"},{"key":"1729_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","volume":"97","author":"A Tajima","year":"2009","unstructured":"Tajima A, Yokoi T, Ariga M, Ito T, Kaneshiro E, Eto Y, et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab. 2009;97:272\u201377.","journal-title":"Mol Genet Metab"},{"key":"1729_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2021.08.230","volume":"175","author":"SRL Vieira","year":"2021","unstructured":"Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med. 2021;175:42\u201355.","journal-title":"Free Radic Biol Med"},{"key":"1729_CR36","first-page":"3397","volume":"89","author":"WM Zhang","year":"2009","unstructured":"Zhang WM, Tang NL, Meng Y, Yao FX, Qiu ZQ, Duan YL, et al. [An analysis of mutations causing Gaucher disease in Chinese population]. Zhonghua Yi Xue Za Zhi. 2009;89:3397\u2013400.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1729_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567\u201383.","journal-title":"Hum Mutat"},{"key":"1729_CR38","doi-asserted-by":"crossref","unstructured":"Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson\u2019s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells. 2019;8:364.","DOI":"10.3390\/cells8040364"},{"key":"1729_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101414","volume":"70","author":"DW Dekens","year":"2021","unstructured":"Dekens DW, Eisel ULM, Gouweleeuw L, Schoemaker RG, De Deyn PP, Naude PJW. Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases. Ageing Res Rev. 2021;70:101414.","journal-title":"Ageing Res Rev"},{"key":"1729_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07469-4","volume":"16","author":"C Guo","year":"2025","unstructured":"Guo C, Li W, Liu Y, Mahaman Yacoubou AR, Wang J, Liu R, et al. LCN2 induces neuronal loss and facilitates sepsis-associated cognitive impairments. Cell Death Dis. 2025;16:146.","journal-title":"Cell Death Dis"},{"key":"1729_CR41","doi-asserted-by":"crossref","unstructured":"Kang H, Shin HJ, An HS, Jin Z, Lee JY, Lee J, et al. Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer\u2019s Disease. Antioxidants (Basel). 2021;10:1657.","DOI":"10.3390\/antiox10111657"},{"key":"1729_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s10072-021-05579-3","volume":"43","author":"M Xiong","year":"2022","unstructured":"Xiong M, Qian Q, Liang X, Wei YD. Serum levels of lipocalin-2 in patients with Parkinson\u2019s disease. Neurol Sci. 2022;43:1755\u201359.","journal-title":"Neurol Sci"},{"key":"1729_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116947","volume":"177","author":"R Qiu","year":"2024","unstructured":"Qiu R, Cai Y, Su Y, Fan K, Sun Z, Zhang Y. Emerging insights into Lipocalin-2: Unraveling its role in Parkinson\u2019s Disease. Biomed Pharmacother. 2024;177:116947.","journal-title":"Biomed Pharmacother"},{"key":"1729_CR44","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41418-023-01216-y","volume":"30","author":"SY Jiang","year":"2023","unstructured":"Jiang SY, Tian T, Yao H, Xia XM, Wang C, Cao L, et al. The cGAS-STING-YY1 axis accelerates progression of neurodegeneration in a mouse model of Parkinson\u2019s disease via LCN2-dependent astrocyte senescence. Cell Death Differ. 2023;30:2280\u201392.","journal-title":"Cell Death Differ"},{"key":"1729_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13578-021-00686-2","volume":"11","author":"JA Choi","year":"2021","unstructured":"Choi JA, Cho SN, Lee J, Son SH, Nguyen DT, Lee SA, et al. Lipocalin 2 regulates expression of MHC class I molecules in Mycobacterium tuberculosis-infected dendritic cells via ROS production. Cell Biosci. 2021;11:175.","journal-title":"Cell Biosci"},{"key":"1729_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/antiox10010100","volume":"10","author":"HJ Shin","year":"2021","unstructured":"Shin HJ, Jeong EA, Lee JY, An HS, Jang HM, Ahn YJ, et al. Lipocalin-2 Deficiency Reduces Oxidative Stress and Neuroinflammation and Results in Attenuation of Kainic Acid-Induced Hippocampal Cell Death. Antioxidants (Basel). 2021;10:100.","journal-title":"Antioxidants (Basel)"},{"key":"1729_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.922534","volume":"9","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zhang N, Xie C, You Y, Guo L, Ye F, et al. Lipocalin-2 in neutrophils induces ferroptosis in septic cardiac dysfunction via increasing labile iron pool of cardiomyocytes. Front Cardiovasc Med. 2022;9:922534.","journal-title":"Front Cardiovasc Med"},{"key":"1729_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","volume":"13","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kim D, Kim S, Kim S, Karuppagounder SS, Kwon SH, et al. alpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener. 2018;13:1.","journal-title":"Mol Neurodegener"},{"key":"1729_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pneurobio.2013.11.005","volume":"114","author":"RA Stetler","year":"2014","unstructured":"Stetler RA, Leak RK, Gan Y, Li P, Zhang F, Hu X, et al. Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance. Prog Neurobiol. 2014;114:58\u201383.","journal-title":"Prog Neurobiol"},{"key":"1729_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.08.021","volume":"31","author":"Y Guo","year":"2023","unstructured":"Guo Y, Chen J, Ji W, Xu L, Xie Y, He S, et al. High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain. Mol Ther Methods Clin Dev. 2023;31:101102.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1729_CR51","doi-asserted-by":"crossref","unstructured":"Johnston S, Parylak SL, Kim S, Mac N, Lim C, Gallina I, et al. AAV ablates neurogenesis in the adult murine hippocampus. Elife. 2021;10:e59291.","DOI":"10.7554\/eLife.59291"},{"key":"1729_CR52","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41420-022-01063-9","volume":"8","author":"Q Cao","year":"2022","unstructured":"Cao Q, Zou Q, Zhao X, Zhang Y, Qu Y, Wang N, et al. Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity. Cell Death Discov. 2022;8:267.","journal-title":"Cell Death Discov"},{"key":"1729_CR53","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1073\/pnas.0813361106","volume":"106","author":"PC Chen","year":"2009","unstructured":"Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson\u2019s disease: Critical role for the astrocyte. Proc Natl Acad Sci USA. 2009;106:2933\u20132938.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1729_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","volume":"298","author":"L Smith","year":"2017","unstructured":"Smith L, Mullin S, Schapira AHV. Insights into the structural biology of Gaucher disease. Exp Neurol. 2017;298:180\u201390.","journal-title":"Exp Neurol"},{"key":"1729_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Toffoli M, Schapira AHV. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol Ther. 2023;246:108419.","journal-title":"Pharmacol Ther"},{"key":"1729_CR56","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292\u201395.","journal-title":"Science"},{"key":"1729_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo SH, Tasset I, Cheng MM, Diaz A, Pan MK, Lieberman OJ, et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by blockade of chaperone-mediated autophagy. Sci Adv. 2022;8:eabm6393.","journal-title":"Sci Adv"},{"key":"1729_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat Commun. 2021;12:1807.","journal-title":"Nat Commun"},{"key":"1729_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41593-021-00989-0","volume":"25","author":"R Wright","year":"2022","unstructured":"Wright R. Mitochondrial dysfunction and Parkinson\u2019s disease. Nat Neurosci. 2022;25:2.","journal-title":"Nat Neurosci"},{"key":"1729_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden P, Perez MJ, Raji H, Bertoli F, Kalb S, Illescas M, et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun. 2023;14:1930.","journal-title":"Nat Commun"},{"key":"1729_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27.","journal-title":"Nat Rev Dis Primers"},{"key":"1729_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108964","volume":"207","author":"RX Bo","year":"2022","unstructured":"Bo RX, Li YY, Zhou TT, Chen NH, Yuan YH. The neuroinflammatory role of glucocerebrosidase in Parkinson\u2019s disease. Neuropharmacology. 2022;207:108964.","journal-title":"Neuropharmacology"},{"key":"1729_CR63","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/jphp.13109","volume":"71","author":"N Mannan Thodukayil","year":"2019","unstructured":"Mannan Thodukayil N, Antony J, Thomas P, Jeyarani V, Choephel T, Manisha C, et al. Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels. J Pharm Pharmacol. 2019;71:1271\u201381.","journal-title":"J Pharm Pharmacol"},{"key":"1729_CR64","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s12013-014-0077-3","volume":"70","author":"H Lv","year":"2014","unstructured":"Lv H, Liu J, Wang L, Zhang H, Yu S, Li Z, et al. Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson\u2019s disease. Cell Biochem Biophys. 2014;70:1433\u201338.","journal-title":"Cell Biochem Biophys"},{"key":"1729_CR65","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s12035-021-02687-1","volume":"59","author":"J Cui","year":"2022","unstructured":"Cui J, Yuan Y, Wang J, Song N, Xie J. Desferrioxamine Ameliorates Lipopolysaccharide-Induced Lipocalin-2 Upregulation via Autophagy Activation in Primary Astrocytes. Mol Neurobiol. 2022;59:2052\u201367.","journal-title":"Mol Neurobiol"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01729-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01729-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01729-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:02:27Z","timestamp":1774962147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01729-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":65,"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01729-2","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal experiments were approved by the Animal Ethics Committee of the School of Basic Medical Sciences, Fudan University (No. 20240229-122), and were performed according to the relevant guidelines and regulations. No experiments using samples from patients have been performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}